Clear All
757 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9360 Vinblastine Oncovin, Vincasar PFS 1 mg Chemotherapy Antimitotic Agent Vinca Alkaloid No 1965 Jan 1, 1986 In Use
J9361 Efbemalenograstim alfa-vuxw Ryzneuta 0.5mg Immunotherapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2023 Jun 10, 2024 In Use
J9370 Vincristine Oncovin, Vincasar PFS 1 mg Chemotherapy Antimitotic Agent Vinca Alkaloid No 1963 Jan 1, 1986 In Use
J9371 Vincristine Oncovin, Vincasar PFS 1 mg Chemotherapy Antimitotic Agent Vinca Alkaloid No 1963 Jan 1, 2014 Jun 10, 2024 No Longer Used
J9375 Vincristine Oncovin, Vincasar PFS 2 mg Chemotherapy Antimitotic Agent Vinca Alkaloid No 1963 Jan 1, 1988 Dec 31, 2010 No Longer Used
J9380 Teclistamab cqyv Tecvayli 0.5mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2022 Jul 11, 2023 In Use
J9380* Vincristine Oncovin, Vincasar PFS 5 mg Chemotherapy Antimitotic Agent Vinca Alkaloid No 1963 Jan 1, 1994 Dec 31, 2010 No Longer Used
J9382 Zenocutuzumab-zbco Bizengri 1mg Immunotherapy Bispecific Antibody HER2, HER3 No 2024 Jul 9, 2025 In Use
J9390 Vinorelbine Navelbine 10 mg Chemotherapy Antimitotic Agent Vinca Alkaloid No 1994 Jan 1, 1996 In Use
J9393 Fulvestrant (Teva) Fulvestrant (Teva) 25mg Hormonal Therapy Estrogen Receptor Antagonist No 2019 Dec 21, 2022 In Use
J9394 Fulvestrant (Fresnius) Fulvestrant (Fresnius) 25mg Hormonal Therapy Estrogen Receptor Antagonist No 2019 Dec 21, 2022 In Use
J9395 Fulvestrant Faslodex 25 mg Hormonal Therapy Estrogen Receptor Antagonist No 2002 Jan 1, 2004 In Use
J9400 Ziv-aflibercept Zaltrap 1 mg Chemotherapy Recombinant Fusion Protein VEGF-IgG1 No 2012 Jan 1, 2014 In Use
J9600 Porfimer Photofrin 75 mg Chemotherapy Photosensitizing Agent Cytotoxin No 1995 Jan 1, 1998 In Use
J9999 Chemotherapy - non specific Not otherwise classified, antineoplastic drugs NA Chemotherapy No In Use
NA Pemigatinib Pemazyre 4.5mg, 9mg, 13.5mg Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3 Yes 2020 In Use
NA Pirtobrutinib Jaypirca Multiple Chemotherapy Tyrosine Kinase Inhibitor BTK Yes 2023 In Use
NA Bosutinib Bosulif 500 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2012 In Use
NA Alpelisib Piqray 150mg Chemotherapy Enzyme Inhibitor PI3K Yes 2019 In Use
NA Estrogens, Esterified Covaryx, Covaryx H.S., Menest, Ogen, Ortho-Est 0.625 mg Hormonal Therapy Estrogen Yes 1977 In Use
NA Panobinostat Farydak 10 mg Chemotherapy Enzyme Inhibitor HDAC Yes 2015 In Use
NA Encorafenib Braftovi 50mg, 75mg Chemotherapy BRAF Inhibitor V600E Yes 2018 In Use
NA Dasatinib Sprycel 20 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
NA Darolutamide Nubeqa 300mg Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Yes 2019 In Use
NA Dasatinib Sprycel 100 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.